Over the past years, vaccinations using heteroclitic peptides from tumour-associated antigens, such as RAS [10], melanoma antigen recognised by T cells 1 (MART1) and glycoprotein 100 (gp100), have been widely employed with the intent to treat cancer patients [11,12,13,14]. The gene discussed is PMEL; the disease is neoplasm.